Mydocalm pills 50 mg 30 pcs
Condition: New product
989 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Tolperisone
Release form
Pills
Composition
Tolperisone hydrochloride 50 mg Auxiliary substances: citric acid monohydrate - 0.73 mg, colloidal silicon dioxide - 0.8 mg, stearic acid - 1.7 mg, talc - 4.5 mg, microcrystalline cellulose - 14 mg, starch cornstarch - 29.77 mg, lactose monohydrate - 48.5 mg. Comp. film cover: colloidal silicon dioxide - 0.045 mg, titanium dioxide (E171) - 0.244 mg, lactose monohydrate - 0.392 mg, macrogol 6000 - 0.392 mg, hypromellose - 3.927 mg.
Pharmacological effect
A muscle relaxant centrally acting. The mechanism of action is not fully understood. It has a membrane stabilizing, local anesthetic effect, inhibits the conduction of pulses in the primary afferent fibers and motor neurons, which leads to the blocking of spinal mono- and polysynaptic reflexes. It is also likely that it again inhibits the release of mediators by inhibiting the entry of Ca2 + into synapses. In the brainstem, it removes the relief of arousal along the reticulospinal pathway. Enhances peripheral blood flow regardless of the influence of the central nervous system. The weak spasmolytic and adrenoceptor blocking effect of tolperisone plays a role in the development of this effect.
Pharmacokinetics
After oral administration, tolperisone is well absorbed from the gastrointestinal tract. Cmax is reached after 0.5–1 h, bioavailability is about 20%. Tolperisone is metabolized in the liver and kidneys. Excreted in the urine as metabolites (more than 99%). Pharmacological activity of metabolites is unknown.
Indications
Treatment of pathologically increased muscle tone and spasms of striated muscles arising from organic diseases of the central nervous system (lesion of the pyramidal tract, multiple sclerosis, cerebral stroke, myelopathy, encephalomyelitis); treatment of increased tone and muscle spasms, muscle contractures, accompanying diseases of the organs of movement (including spondylosis, spondyloarthrosis, cervical and lumbar syndromes, arthrosis of large joints); rehabilitation treatment after orthopedic and trauma surgeries; as part of combination therapy for vascular disease obliterans (obliterating atherosclerosis, diabetic angiopathy, thromboangiitis obliterans, Raynaud’s disease, diffuse scleroderma), diseases arising on the basis of vascular innervation disorder (acrocyanosis, intermittent angioedema); Little's disease (pediatric cerebral palsy) and other encephalopathies accompanied by muscular dystonia.
Contraindications
Hypersensitivity to any of the components of the drug; myasthenia gravis; children's age up to 3 years.
Use during pregnancy and lactation
Due to the lack of data on the use during pregnancy and breastfeeding, the prescription of Mydocalm is not recommended during these periods.
Dosage and administration
Inside, after eating, without chewing, drinking a small amount of water. Adults and children from 14 years old - usually from 50 mg 2-3 times a day, gradually increasing the dose to 150 mg 2-3 times a day. Children from 3 to 6 years old - Mydocalm is administered orally at a daily dose of 5 mg / kg; 7–14 years old - 2–4 mg / kg (in 3 doses during the day).
Side effects
Muscle weakness, headache, hypotension, nausea, vomiting, feeling of abdominal discomfort. By reducing the dose, side effects usually disappear. In rare cases, allergic reactions occur (pruritus, erythema, urticaria, angioedema, anaphylactic shock, bronchospasm).
Overdose
Data overdose drug Mydocalm has been reported. Treatment: recommended gastric lavage, symptomatic therapy. There is no specific antidote.
Interaction with other drugs
Data on interactions that limit the use of the drug Mydocalm, not available. Although tolperisone has an effect on the central nervous system, it does not cause a sedative effect, therefore it can be used in combination with sedatives, hypnotics and drugs containing alcohol. Does not affect the effect of alcohol on the central nervous system. Tolperisone enhances the action of niflumic acid, while the use of these drugs may require a reduction in the dose of niflumic acid. Funds for general anesthesia, peripheral muscle relaxants, psychotropic drugs, clonidine - enhance the effect of tolperisone.
special instructions
Apply strictly on doctor's prescription to avoid complications. Influence on ability to drive vehicles and mechanisms. Studies have not been conducted, but for many years of practice using the drug such information has not been reported.